Lymphoma

ABVD + Rituximab Nodular Lymphocyte Prominent Hodgkin’s Lymphoma and Nodular Lymphocyte Prominent B-Cell Lymphoma V1.0

Acalabrutinib (monotherapy) Chronic Lymphocytic Leukaemia Protocol V1.1

BeGEV Relapsed or Refractory Hodgkin Lymphoma v1.0

BCHP (Brentuximab, Cyclophosphamide, Doxorubicin) Systemic Anaplastic Large Cell Lymphoma V2.0

Brentuximab Hodgkin’s Lymphoma - Systemic Anaplastic Large Cell Lymphoma and CD30+ Cutaneous T-cell Lymphoma Protocol V2.0

CHOP + / - Rituximab Non-Hodgkin’s Lymphoma Protocol V2.0

CVP + / - Rituximab Non-Hodgkin’s Lymphoma Protocol V2.0

Dose Adjusted (DA) EPOCH +/- Rituximab High Grade Non-Hodgkin Lymphoma V1.0

DDGP - Dexamethasone, Cisplatin, Gemcitabine and Peg-aspargase v1.0

DHAP +- Rituximab Relapsed or Refractory Lymphoma V1.0

Escalated BEACOPDac High Grade Hodgkin Lymphoma V1.0

Escalated BEACOPP Hodgkin’s Lymphoma Protocol V1.1

ESHAP +- Rituximab Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma V1.0

GCVP +/- Rituximab Non Hodgkins Lymphoma V1.0

GDP +- Rituximab Relapsed or Refractory Hodgkin's or Non-Hodgkin's Lymphoma V2.0

High Dose Methotrexate CNS NHL Prophylaxis V1.0

High Dose Methotrexate Overview Leukaemia Lymphoma V2.0

Ibrutinib Chronic Lymphocytic Leukaemia & Lymphoma Protocol V2.0

Ibrutinib and Venetoclax Chronic Lymphocytic Leukaemia (CLL) V1.0

Imatinib v2.0

ICE +- Rituximab (INPATIENT) Relapsed or Refractory Lymphoma V1.0

ICE +- Rituximab (OUTPATIENT) Relapsed or Refractory Lymphoma V1.0

IGEV +- Rituximab Relapsed or Refractory Hodgkin's or Non-Hodgkin's Lymphoma V1.0

IVE +- Rituximab Relapsed or Refractory Lymphoma V1.0

Lyaspmedex PEG Asparaginase, Methotrexate, Dexamethasone V2.0

MATRIX Primary CNS Lymphoma V2.1

Mini-CHOP +/ - Rituximab Non-Hodgkin’s Lymphoma Protocol V1.0

Mogamulizumab Mycosis Fungoides Sezary Syndrome V1.0

Nivolumab Relapsed Refractory Hodgkin’s Lymphoma V2.0

Nordic (R-maxi-CHOP alternating with R- HD cytarabine) Mantle Cell Lymphoma Protocol V2.0

Obinutuzumab & Bendamustine - Previously Untreated & Relapsed or Refractory Follicular Lymphoma Protocol V1.0

Obinutuzumab & CHOP - Previously Untreated Follicular Lymphoma Protocol V1.0

Obinutuzumab & CVP - Previously Untreated Follicular Lymphoma Protocol V1.0

Obinutuzumab Maintenance - Follicular Lymphoma Protocol V1.0

Obinutuzumab and Venetoclax Chronic Lymphocytic Leukaemia Protocol V1.0

Pembrolizumab Relapsed Refractory Hodgkin's Lymphoma V2.0

Polatuzumab Vedotin, Rituximab and Bendamustine Diffuse Large B Cell Lymphoma (DLBCL) V2.0

R-BAC Relapsed-Refractory Non-Hodgkin’s Lymphoma Protocol V2.0

R-CODOX-M / R-IVAC Burkitt Lymphoma / DLBCL with adverse features V1.0

Rituximab Administration Guideline V1.0

Rituximab Single Agent v 2.0

Rituxumab-Bendamustine for First Line CLLL and Low Grade NHL v2.0

Rituximab-Chlorambucil Chronic Lymphocytic Leukaemia Protocol V2.0

Rituximab, Fludarabine and Cyclophosphamide (R-FC) Chronic Lymphocytic Leukaemia Protocol V1.0

Rituximab-Lenalidomide (R2) Relapsed-Refractory NHL Compassionate Use v2.0

Rituximab-Lenaldomide (R2) Relapse Follicular Lymphoma v 2.0

Rituximab-Polatuzumab-CHP Diffuse Large B Cell Lymphoma (DLBCL) V2.0

RMP (Rituximab, Methotrexate, Procarbazine) Primary CNS Lymphoma V3.0

R-MAA - Rituximab, Methotrexate & Cytarabine Primary CNS Lymphoma V1.0

Maintenance Subcutaneous (sc) Rituximab B-Cell Lymphomas V2.0

Venetoclax +/- Rituximab Chronic Lymphocytic Leukaemia Protocol V3.0

Vinblastine monotherapy Relapsed / Refractory T Cell Lymphomas V1.0

Zanubrutinib Waldenstrom’s Macroglobulinaemia V1.0